IP Library › Granted Patent US 9,427,354
Granted Patent B2
US 9,427,354 · App. 13/825,176 · Granted Aug 30, 2016

Material for medical use comprising nanoparticles with superparamagnetic properties and its utilization in surgery

Inventors: Roberto Zysler (Rio Negro, AR); Alejandro Berra (Ciudad Autónoma de Buenos Aires, AR); Pablo Gurman (Richardson, TX); Orlando Hector Auciello (Garland, TX); Mario Joaquin Saravia (Buenos Aires, AR)
Assignee: NANOPHTHALMICS, LLC
A61F9/007A61F9/00727A61K9/0048A61K9/0051A61K9/5094A61K9/5115A61K9/5146A61L27/042A61L27/54A61L2300/44A61L2400/06A61L2400/12A61L2430/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,427,354
App. No.
13/825,176
Granted
Aug 30, 2016
Kind
B2
Abstract

This invention relates to a material for medical use that comprises biocompatible nanoparticles having superparamagnetic properties, where the superparamagnetic properties of said nanoparticles are used to localize their action on a determined space or tissue. In particular, said nanoparticles having superparamagnetic properties are composed of magnetite. The material according to the invention has various applications, both in surgical and in therapeutic treatments.

Claims (10)

1. A procedure for tamponading a patient's retina, comprising the following steps in order:

i. submitting the patient to a vitrectomy;

ii. injecting a material into the patient's intravitreous space, wherein the material is in the form of a liquid suspension comprising biocompatible nanoparticles having superparamagnetic properties, and the liquid suspension does not contain a polymeric material; and

iii. through application of a magnetic field created by a magnet located outside the eye, attract the nanoparticles to push and maintain the retina applied against an inner wall of the patient's eye,

wherein a step of polymerizing the nanoparticles does not take place between steps ii and iii.

2. The procedure according to claim 1 , wherein the nanoparticles may exert their action equally for upper injuries and for lower injuries.

3. The procedure according to claim 2 , wherein the nanoparticles are injected together with a pharmaceutically acceptable vehicle or carrier contained in the liquid suspension or in a composition separate from the liquid suspension.

4. The procedure of claim 1 , further comprising the steps of

iv. removing the magnetic field applied in step iii,

v. allowing the nanoparticles to be absorbed by the patient's eye tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2013
From: ZYSLER, ROBERTO; BERRA, ALEJANDRO; GURMAN, PABLO; AUCIELLO, ORLANDO; SARAVIA, MARIO JOAQUIN
To: NANOPHTHALMICS, LLC
Reel/Frame 030355/0600 →
Priority Claims (1)
AR P20100103421 · Sep 20, 2010 · national
Continuity (1)
Related Publication 20130225906A1 · Aug 29, 2013